-5.41% were down 1.1% in premarket trading on Monday after the drugmaker said the first patient had been enrolled in a late-stage trial assessing rheumatoid arthritis drug Olumiant as a treatment for COVID-19.American depositary shares of Chinese electric-car maker Li Auto Inc.  skyrocketed nearly 50% to trade above $16 on Thursday after pricing their initial public offering at $11.50 an ADS.